
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 12, 2026, 8:00 AM ET
Artelo Biosciences reported a third quarter 2026 net loss of $1.8 million and cash of $4.4 million as of September 30, 2026.
$ARTLBiotech · Neurology and metabolismDated financialsExecution and funding risk
ARTL Stock Hub: Artelo Biosciences News, Operations and Capital
An obesity hypothesis joins the human pipeline. DREAM results and a repeat-dose study face the same practical question: sufficient financing to reach useful evidence. On November 12, 2026 Artelo reported $4.4 million of cash at September 30, and its quarterly report again disclosed substantial doubt about its ability to continue as a going concern.
Full research report · PDF
Artelo Biosciences ($ARTL), research updated November 12, 2026
13 pages covering the third-quarter 2026 results of November 12, the September 30 balance sheet and nine-month operating cash use, the at-the-market issuance and going-concern disclosure, DREAM, ART26.12 and ART27.13, the reverse split, warrants, the Craft arbitration, scenarios, sources and FAQ. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next financial and operating checkpoint
Q4 2026 · Initial DREAM glaucoma results
Company development target announced August 10, 2026, which anticipates initial results in Q4 2026 without an exact date; this is a clinical readout target, not a confirmed event date. The November 12, 2026 update reported enrollment underway in the investigator-led DREAM study and did not restate a results date. Company disclosure
ART26.12: the November 12 update anticipates a Phase 1 multiple ascending dose study initiating in the fourth quarter of 2026, subject to execution and funding. Artelo presented ART26.12 data at the IASP 2026 World Congress on Pain and at BIO-Europe 2026. November 12 update
ARTL stock at a glance
Chart analysis · JC
Technical chart analysis of $ARTL with bull and bear scenarios on JC Just Charts.
SHORT INTEREST
27,721
October 30, 2026 settlement; about 3.0% of the 937,177 shares outstanding, a calculation · Nasdaq
Where Artelo Biosciences stands now
An obesity hypothesis joins the human pipeline. DREAM results and a repeat-dose study face the same practical question: sufficient financing to reach useful evidence. Source Source
On November 12, 2026 Artelo reported a third-quarter net loss of $1.8 million, or $3.19 per basic and diluted share, against $3.1 million a year earlier, with research and development expenses of $0.8 million and general and administrative expenses of $1.0 million. Cash was $4.437 million at September 30; nine-month operating cash use was $8.849 million. Through September 30 the at-the-market program had sold 432,062 shares for net proceeds of $3.0 million, and 937,177 shares were outstanding on November 11, 2026. The quarterly report states that the company will be required to raise additional funds and that these conditions raise substantial doubt about its ability to continue as a going concern within one year. On the pipeline, the company reported nonclinical obesity findings for ART27.13, Notices of Allowance in the U.S. and Japan for claims covering the intended commercial formulation of ART27.13, enrollment underway in the investigator-led DREAM glaucoma study, and a planned fourth-quarter 2026 start of the ART26.12 multiple ascending dose study. November 12 update Form 10-Q, September 30, 2026
The main constraint. Financing, not science, is what limits the timeline: $4.437 million of cash at September 30, 2026 against $8.849 million of nine-month operating use, with the quarterly report stating substantial doubt about the ability to continue as a going concern. The August consolidation changed how the stock is denominated; it did not add capital. Form 10-Q
The constructive case
The constructive case would require useful human results, continued development and financing on terms that leave existing shareholders with a meaningful interest in the outcome. Artelo’s August 10, 2026 announcement targets initial DREAM glaucoma results later in 2026, while its August 13 update targets the ART26.12 multiple-dose study for the fourth quarter. Those are prospective milestones. The obesity findings announced in September add an experimental opportunity, but remain mouse data. Source Source Source
The cautious case
The adverse case would involve disappointing human results, slower development or financing that materially reduces existing holders’ economic interest. The June and September 2026 financial statements explicitly identify substantial doubt about the company’s ability to continue as a going concern. The August share consolidation changes the denomination of the stock; it does not solve the operating funding gap. Source Source
Latest Artelo Biosciences news
Nov 12, 2026
Artelo Biosciences provides business update and reports 2026 third quarter financial results
Artelo reported nonclinical findings showing approximately 20% weight loss with ART27.13 monotherapy and approximately 40% weight loss when combined with semaglutide in a diet-induced obesity animal model. Plans for ART26.12 anticipate a Phase 1 multiple ascending dose (MAD) study to initiate in the fourth quarter of 2026. For the quarter ended September 30, 2026, research and development expenses were $0.8 million and net loss was $1.8 million, or $3.19 per basic and diluted common share, compared to a net loss of $3.1 million a year earlier. Cash totaled $4.4 million as of September 30, 2026.
Oct 29, 2026
ART27.13 nonclinical pain work presented at IASP
The company scheduled presentation of animal-model neuropathic-pain findings for October 29. These experiments do not demonstrate efficacy in patients; pain endpoints remain part of the ongoing CAReS study.
Oct 26, 2026
ART26.12 data scheduled at the IASP 2026 World Congress on Pain on October 29
Artelo announced that its Vice President of Translational Sciences is scheduled to present data on ART26.12, its peripherally acting FABP5 inhibitor, at the IASP 2026 World Congress on Pain in Bangkok (October 26–30), on October 29. The presentation covers nonclinical work in painful neuropathies and osteoarthritis and the completed Phase 1 single-ascending-dose study, in which the company reported no serious adverse events attributed to ART26.12 and dose-proportional pharmacokinetics; the release gives no numerical results. Artelo said it is preparing to start the Phase 1 multiple-ascending-dose study in the fourth quarter of 2026 and has initiated steps to begin enrollment. A conference presentation is not an efficacy result in patients. Artelo press release, October 26, 2026
Oct 9, 2026
Nasdaq proposed $5 million MVLS rule is stayed; no immediate delisting decision
Artelo's October 9 Form 8-K discusses the proposed Nasdaq $5 million minimum market value of listed securities requirement. The rule proposed on October 5 is temporarily stayed and would become operative when the stay ends; the comment deadline is October 29. This filing does not announce immediate delisting or a selected financing transaction. The conditional listing risk is not an already effective new requirement. Source: SEC filing
Oct 7, 2026
First company presentation at BIO-Europe, November 10
Artelo will present at BIO-Europe 2026 in Cologne on November 10 at 4:15 p.m. CET, its first company presentation at the partnering meeting. The chief scientific officer is to cover ART26.12 Phase 1 safety and pharmacokinetics, food-effect results and preclinical work in chemotherapy-induced peripheral neuropathy and osteoarthritis. A partnering presentation of existing data, not a new clinical readout.
Sep 23, 2026
provisional obesity patent application
Artelo filed a provisional application for ART27.13 alone and with GLP-1 receptor agonists following mouse findings. The filing is not an issued patent or human efficacy evidence.
ARTL stock catalysts: operating and financial milestones
- November 10, 2026 — BIO-Europe company presentation of ART26.12 data. Held, per the November 12 update
- November 12, 2026 — Third-quarter 2026 results and Form 10-Q: cash of $4.437 million at September 30 and continuing going-concern doubt. Completed
- Q4 2026 — Initial DREAM glaucoma results. Company target of August 10, 2026; not restated on November 12
- Q4 2026 — ART26.12 Phase 1 multiple ascending dose study start, reaffirmed November 12, 2026. Company target, subject to execution and financing
November 12, 2026 disclosure October 26, 2026 disclosure October 9, 2026 disclosure October 7, 2026 disclosure
Artelo pipeline at a glance
PHASE 1b/2a · TWO PHASE 2 STUDIES
ART27.13 · peripheral CB1/CB2 agonist
A dual cannabinoid receptor agonist licensed from AstraZeneca, designed to act on peripheral receptors. It is in the Cancer Appetite Recovery Study for cancer-related anorexia, where an interim analysis reported more than 6% mean weight gain against a 5% loss on placebo in eighteen evaluable patients, and in the investigator-led DREAM study in glaucoma or ocular hypertension in the United Kingdom. Nonclinical obesity work reported approximately 20% weight loss as a monotherapy and approximately 40% with semaglutide in mice. Form 10-Q
PHASE 1 · SINGLE ASCENDING DOSE COMPLETE
ART26.12 · FABP5 inhibitor
The first selective fatty acid binding protein 5 inhibitor the company has taken into people. The investigational new drug application cleared in July 2024 and the single ascending dose study enrolled forty-nine healthy volunteers with mild, transient adverse events and dose-dependent linear absorption. A multiple ascending dose study is planned for the fourth quarter of 2026. Preclinical work covers chemotherapy-induced peripheral neuropathy, spinal cord injury and osteoarthritis. Form 10-Q
PRECLINICAL · FORMULATION PROGRAM
ART12.11 · CBD cocrystal
A wholly owned cocrystal of cannabidiol and tetramethylpyrazine, isolated as a single crystalline form. Cocrystals change the physical behaviour of a known molecule — solubility, stability, absorption — and can support composition-of-matter protection. The company lists dermatologic conditions, anxiety and inflammation among the potential uses. Form 10-Q
The financing position after the third quarter
| Item | Detail |
|---|---|
| Cash | $4.437 million at September 30, 2026, against $600,000 at December 31, 2025 |
| Operating cash use | $8.849 million in the nine months to September 30, 2026, against $5.609 million a year earlier |
| Historical ratio | About four and a half months at the nine-month rate, a Merlintrader calculation rather than a forecast |
| Going concern | The quarterly report states that conditions raise substantial doubt about the ability to continue as a going concern within one year |
| At-the-market program | Up to $6.53 million of common stock through H.C. Wainwright at a 3.0% commission; 432,062 shares sold for $3.0 million net through September 30 |
| Shelf registration | $75 million on Form S-3, effective May 19, 2026 |
| Convertible debt | None outstanding at September 30, 2026; $609,000 of notes and related-party notes were repaid during the year |
| Instruments outstanding | 784,424 warrants at a $37.16 weighted average exercise price and 22,902 options at $139.86, both with zero intrinsic value at September 30 |
Sources: Form 10-Q for the quarter ended September 30, 2026, filed November 12, 2026.
Artelo Biosciences deep dive: the full analysis
The chapters below work through the company in detail: the scenarios, the three programs and the evidence behind each, the third-quarter 2026 accounts, the going-concern disclosure, the capital structure after the reverse split, the arbitration and the listing question. The same research is available as a downloadable PDF in the Research Library. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Three scenarios: the science is cheap to advance, the company is not funded to finish it
Bull case — human evidence arrives before the money runs out
The favorable path does not require a commercial launch. It requires two pieces of usable human evidence and one financing on tolerable terms. The first piece is a DREAM result showing that oral ART27.13 lowers intraocular pressure in patients with glaucoma or ocular hypertension, because that would give a peripheral cannabinoid agonist a second clinical indication beyond cancer anorexia. The second is a clean multiple ascending dose study for ART26.12, which would move the FABP5 program from forty-nine healthy volunteers to a dose range that can be tested in patients with chemotherapy-induced peripheral neuropathy. The financing is the third leg: at September 30, 2026 the company held $4.437 million, and the quarterly report states that conditions raise substantial doubt about its ability to continue as a going concern within one year. A partnering or licensing deal on ART27.13 — the company says the obesity work is producing interest from potential strategic partners in new therapeutic markets — would bridge without issuing equity at the current share count. Form 10-Q, September 30, 2026
Base case — evidence accumulates slowly, financing is raised in pieces
The more likely path is a sequence of small steps financed by small raises. Artelo has run this pattern for several years: the at-the-market program sold 432,062 shares for $3.0 million of net proceeds through September 30, 2026, a March 2026 private placement brought in gross proceeds of $10,997,000, and convertible notes were mostly repaid during the year, with $208,000 converted into shares in the first quarter. Each step extends the calendar by a few months and adds shares. In this scenario DREAM reports whenever the investigator-led site network is ready, ART26.12 starts its multiple ascending dose study late or early 2027 depending on cash, and the share count keeps rising while the programs stay investigational. The company survives, the science advances, and the per-share claim on the outcome shrinks. Form 10-Q, September 30, 2026
Bear case — the financing gap closes on terms that leave little for existing holders
The adverse path is arithmetic rather than scientific. Nine-month operating cash use was $8.849 million against $4.437 million of cash at September 30. The company has no revenue and does not expect product revenue in the near term. If a financing is priced at a discount after a weak readout, or if the ART26.12 study is delayed for lack of funds, the equity sold to fund the work can absorb most of the value created by it. The Craft arbitration adds a claim that, if decided against the company, would be settled in cash or shares at a moment when neither is abundant. The reverse split, effective August 28, 2026 with adjusted trading from August 31, changed the share denomination and reduced the authorized count; it did not change the funding requirement. Form 10-Q, September 30, 2026 Form 8-K, August 27, 2026
What would falsify this reading
Artelo’s scientific options are broader than its balance sheet, so the reading depends on evidence continuing to arrive and on capital continuing to be available. Four observations would weaken it.
A DREAM result that shows no meaningful reduction in intraocular pressure, or a safety signal at the doses tested, would remove the second indication for ART27.13 and leave the program dependent on cancer anorexia alone. A multiple ascending dose study for ART26.12 that is delayed beyond the first half of 2027, or that shows exposure levels which cannot be maintained within a tolerable safety margin, would push the pain program back into preclinical status. A financing that values the company below the level implied by its cash and the modest remaining enterprise value would show that the market assigns no option value to the pipeline, which is a statement about credibility rather than about science. Finally, a going-concern qualification that is repeated for a fourth consecutive quarter while spending continues would indicate that the incremental raises are not keeping pace with the burn, and that the equity is being consumed rather than invested. Form 10-Q, September 30, 2026
02 What Artelo Biosciences does: lipid signaling, three programs, one platform thesis
Artelo is a clinical-stage company built on a single idea: that the movement of fatty acids inside and between cells is a drug target, not only a metabolic detail. The company describes itself as focused on modulating lipid-signaling pathways, including the endocannabinoid system, a network of receptors and lipid messengers that acts throughout the body. That framing covers three programs at very different stages. ART27.13 is a synthetic dual agonist of the CB1 and CB2 receptors that was initially developed by AstraZeneca and is designed to act on peripheral receptors. ART26.12 is a small-molecule inhibitor of fatty acid binding protein 5, the first selective FABP5 inhibitor the company has taken into humans. ART12.11 is a cocrystal of cannabidiol and tetramethylpyrazine, earlier in development. Form 10-Q, September 30, 2026
The endocannabinoid link matters for how the two lead programs connect. Fatty acid binding proteins transport endocannabinoids such as anandamide inside cells, and the published work on FABP inhibition shows that blocking that transport raises endocannabinoid tone and reduces pain in animal models. In 2014, Kaczocha et al. reported that inhibiting fatty acid binding proteins elevated brain anandamide levels and produced analgesia in mice. Kaczocha et al., PLoS ONE 2014 A 2015 study from the same group found that deleting fatty acid binding protein suppressed inflammatory pain through endocannabinoid and N-acylethanolamine-dependent mechanisms. Kaczocha et al., Molecular Pain 2015 That is the scientific bridge between ART26.12 and ART27.13: one program blocks the transporter that clears the messenger, the other stimulates the receptor the messenger acts on.
The company is based in Solana Beach, California, with subsidiaries in Ireland and the United Kingdom and an administrative office outside Manchester. It owns no laboratories or manufacturing facilities, which is normal for a company of this size and also means that clinical work depends on contract providers and on the cash available to pay them. Gregory D. Gorgas is President and Chief Executive Officer, and Mark E. Spring is Chief Financial Officer and Treasurer; both signed the November 12, 2026 quarterly report. Form 10-Q, September 30, 2026
03 ARTL stock catalysts: the dated milestones and what would count as a pass
Three items carry the calendar, and two of them are targets rather than scheduled events. The company said on August 10, 2026 that it anticipated initial DREAM results in the fourth quarter of 2026, without giving a date; on November 12 it reported enrollment underway and did not restate a results date. The ART26.12 multiple ascending dose study is planned to initiate in the fourth quarter of 2026, a plan the November 12 update repeated without adding a date; the study depends on execution and on the funding available in that quarter. The third item is not a date at all: the chief executive said the expanding potential of ART27.13 was generating opportunities with potential strategic partners in significant new therapeutic markets, a description of interest rather than of a negotiation. November 12, 2026 business update
A pass on DREAM would mean a statistically and clinically meaningful reduction in intraocular pressure in patients with glaucoma or ocular hypertension, measured against the study’s own comparator and reported with the usual safety data. A reduction that is statistically significant but too small to matter clinically, or that comes with systemic cannabinoid effects at the doses required, would be a partial result. A pass on ART26.12 would mean dose-proportional exposure across the ascending cohorts, no dose-limiting adverse events, and a dose range that supports a Phase 2 design in neuropathic pain. A failed study would show saturation of exposure or cumulative tolerability problems, which in a first-in-class molecule is a plausible outcome and the main scientific risk in the calendar. Form 10-Q, September 30, 2026
Investors should also separate the events the company controls from the ones it does not. DREAM is investigator-led in the United Kingdom, so enrolment and reporting depend on the site network as much as on Artelo. The company’s contribution is drug supply and support, and its public statements have respected that distinction by describing enrollment status rather than promising a readout. November 12, 2026 business update
04 The obesity finding: four weeks in mice, and a patent filed within a week
On September 16, 2026 Artelo reported nonclinical results in a diet-induced obesity model: approximately 20% weight loss with ART27.13 as a monotherapy, comparable to semaglutide in the same experiment, and approximately 40% weight loss when the two were combined. The combination also improved oral glucose tolerance and increased bone mineral density, effects the company said were not observed in any other treatment group. On September 23 it filed a provisional patent application covering ART27.13 for obesity and for combination use with GLP-1 receptor agonists. September 16, 2026 release September 23, 2026 release
The qualification is important and the company has kept it: these are mice, over four weeks, in a model that is standard for obesity research and notoriously generous to compounds that reduce food intake. Nothing in the disclosure establishes human weight loss, and the clinical program for ART27.13 in weight management does not yet exist. What the data do establish is a combination hypothesis that is commercially interesting if it survives translation, because a CB1/CB2 peripheral agonist that adds to a GLP-1 without adding central nervous system effects would address the tolerability and lean-mass problems that limit GLP-1 therapy at high doses. The endocannabinoid system’s role in energy balance is well documented; Whiting et al., JAMA 2015 reviewed the clinical evidence for cannabinoids across indications and found modest, indication-specific effects rather than a general metabolic benefit, which is the right prior when reading a mouse result.
There is a second, less obvious point in the September disclosures. The company said the findings were unexpected, and the speed of the patent filing suggests it moved to protect a combination claim rather than an indication claim. Combination claims are valuable when a partner owns the other half of the combination, which is consistent with the November 12 comment about discussions with potential strategic partners. They are also harder to enforce and easier to design around than composition-of-matter claims, so the commercial value depends on what a partner is willing to pay for the hypothesis before human data exist. September 23, 2026 release
05 CAReS and cancer anorexia: a small interim signal that has carried the program
The clinical foundation for ART27.13 is the Cancer Appetite Recovery Study, a Phase 1b/2a trial in patients with cancer-related anorexia. In an interim analysis reported in September 2025, patients receiving ART27.13 showed a mean weight gain of more than 6% against a 5% loss in the placebo group, with a safety profile similar to the earlier phase despite doses up to twice the previous maximum. The quarterly report describes the interim findings as coming from eighteen evaluable patients, with the highest-dose comparison involving five treated and six placebo participants. Form 10-Q, September 30, 2026
Those numbers are a signal, not a result. An eleven-point difference in mean weight change between arms of five and six patients can be produced by the natural history of the disease as easily as by the drug, and cancer anorexia cachexia is a syndrome in which weight change is influenced by tumor type, treatment regimen and inflammation. The company’s own framing has been careful: it refers to previously reported interim findings and does not present them as confirmatory. The regulatory context is what keeps the program alive commercially, because there is no approved treatment for cancer anorexia cachexia syndrome in the United States, a point the quarterly report states directly. Form 10-Q, September 30, 2026
The wider literature is mixed in a way that argues for caution about appetite endpoints. A 2022 systematic review and meta-analysis of cannabinoid interventions for cancer cachexia found limited and inconsistent evidence across trials, with heterogeneity that makes pooled estimates difficult to interpret. Simon et al., Journal of Cachexia, Sarcopenia and Muscle 2022 Appetite stimulation has repeatedly failed to translate into durable gains in lean mass or function, which is why the CAReS data on lean body mass and physical activity, if confirmed in a controlled population, would matter more than the weight figure alone.
06 DREAM: a glaucoma study run by investigators, not by the company
DREAM is a Phase 2 study, led by investigators in the United Kingdom, testing whether daily oral ART27.13 lowers intraocular pressure in people with glaucoma or ocular hypertension. Enrollment is underway, and the company has described the study as a second Phase 2 for the molecule. The scientific rationale is old and better established than the therapeutic one: cannabinoids lower intraocular pressure, and the effect has been measured in small trials for decades. A 2006 pilot study of sublingual cannabinoids reported a reduction in intraocular pressure. Tomida et al., Journal of Glaucoma 2006
The problem that has kept cannabinoids out of clinical glaucoma practice is not efficacy in the short term but the ratio between the dose needed and the systemic effects produced. Oral tetrahydrocannabinol lowers pressure for a few hours at doses that cause psychotropic effects, while glaucoma requires a sustained reduction across the whole day. Work on dronabinol, an oral synthetic cannabinoid, has focused on a different angle: whether it changes ocular blood flow. A randomized trial in healthy subjects examined the effect of oral dronabinol on optic nerve head blood flow, Hommer et al., Clinical Pharmacology & Therapeutics 2020 and a 2025 study reported that a single oral dose increased ocular blood flow in patients with glaucoma. Lindner et al., Acta Ophthalmologica 2025
That literature supports the hypothesis Artelo is testing and also defines what would count as a useful result. A peripheral CB1/CB2 agonist that lowers intraocular pressure without central effects would address exactly the limitation that has blocked the class. A result showing only a transient pressure reduction, or one accompanied by systemic cannabinoid adverse events, would place DREAM alongside the earlier attempts rather than ahead of them. Because the study is investigator-led, the company’s ability to accelerate or shape it is limited, and the fourth-quarter 2026 target for initial results is a company expectation attached to a trial it does not run. November 12, 2026 business update
07 ART26.12 and FABP5: forty-nine volunteers, then the hard part
ART26.12 is the company’s lead FABP5 inhibitor and, it says, the first selective inhibitor of that protein to be evaluated in humans. The Food and Drug Administration cleared the investigational new drug application in July 2024, and the company completed a single ascending dose study in healthy volunteers that enrolled forty-nine subjects. In June 2025 it reported that all adverse events were mild, transient and self-resolving, that no drug-related adverse events appeared in the blinded dataset, and that plasma analysis confirmed dose-dependent, linear absorption across the range tested, with a wide safety margin between estimated therapeutic concentrations and the highest exposures achieved. Form 10-Q, September 30, 2026
The preclinical case for the mechanism is unusually specific. Work from the Kaczocha laboratory showed that pharmacological inhibition of fatty acid binding proteins produces analgesia through both peripheral and central mechanisms, Peng et al., Molecular Pain 2017 and that deleting FABP5 in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain. Bogdan et al., Scientific Reports 2022 In other words, the target has a genetic validation in animals that does not depend on the company’s own molecule, which is a stronger starting point than a compound looking for a mechanism.
The company’s stated preclinical findings place ART26.12 across chemotherapy-induced peripheral neuropathy, spinal cord injury and osteoarthritis, with pain relief comparable to naproxen and significantly less gastric tissue damage in the model described on November 12. Those are animal data. The multiple ascending dose study is what converts them into a human dose range, and it is the single most informative near-term event for this program: a clean result lets the company design a Phase 2 in neuropathic pain, while a tolerability or exposure failure would send the program back to formulation with a balance sheet that cannot easily afford the wait. November 12, 2026 business update
08 ART12.11 and the intellectual property that sits behind the programs
ART12.11 is the smallest of the three programs and the easiest to overlook. It is a wholly owned cocrystal of cannabidiol and tetramethylpyrazine, isolated as a single crystalline form. A cocrystal is a way of changing how a molecule behaves physically — solubility, stability, absorption — without changing the molecule itself, and it can produce composition-of-matter protection around a known substance. Cannabidiol has been studied extensively and its pharmacokinetics are poor: oral bioavailability is low and variable, which is precisely the problem a formulation patent can address. The company lists dermatologic conditions, anxiety and inflammation among the potential uses. Form 10-Q, September 30, 2026
The patent position around ART27.13 is more consequential to the investment case and has improved during 2026. The company received notices of allowance in the United States and Japan for claims covering the intended commercial formulation, and it said the United States patent, once issued, is expected to extend protection through 2041. U.S. notice of allowance Japan notice of allowance A formulation patent matters because it protects the product the company would actually sell, not only the molecule, and it is the kind of asset a partner values when negotiating a license. The September provisional application on obesity and GLP-1 combinations adds a use claim in front of that formulation estate.
There is a caveat worth stating plainly: the intangible asset on the balance sheet is $2.039 million and has not been amortized during 2026, which is consistent with an asset not yet in commercial use. Intellectual property on a development-stage balance sheet is a cost, not a valuation. Its worth depends on whether the claims survive examination and litigation, and on whether a product reaches a market where they can be enforced. Form 10-Q, September 30, 2026
09 Artelo earnings: a third quarter that shrank the loss and shrank the company
The third quarter of 2026 produced a smaller loss on a smaller operation. Research and development expense was $0.8 million against $1.3 million a year earlier, and general and administrative expense was $1.0 million against $1.8 million, taking total operating expenses to $1.792 million from $3.089 million. The net loss was $1.768 million, or $3.19 per basic and diluted share, against $3.120 million a year earlier. Interest income of $24,000 was the only other line of consequence. Form 10-Q, September 30, 2026 November 12, 2026 business update
The nine-month figures tell a different story and are the more informative ones, because they show what happens to a development plan when cash is tight. Research and development fell to $2.452 million from $4.530 million, a reduction of almost half, while general and administrative expense rose to $4.534 million from $4.088 million. Total operating expenses were $6.986 million against $8.618 million, and the nine-month net loss was $7.153 million against $8.713 million. A company that cuts research by 46% while administrative costs grow is funding its corporate existence faster than its science. Form 10-Q, September 30, 2026
Two non-cash items are worth separating from the operating trend. Stock-based compensation of $617,000 ran through the nine-month results, and the company issued common shares as a commitment fee in an equity purchase agreement, at a cost of $500,000. Neither consumes cash, and both increase the share count over time. The company also recognised a $146,000 net change in the fair value of a derivative liability and a $42,000 gain on extinguishment of debt during the nine months; those are accounting effects of the convertible notes that were repaid, not operating outcomes. Form 10-Q, September 30, 2026
10 Cash, burn and the runway that the filing does not promise
Cash was $4.437 million at September 30, 2026, against $600,000 at December 31, 2025. The increase came from financing, not from operations: $13.069 million of net proceeds from share issuance, $593,000 from convertible notes, and $237,000 from warrant exercises, against $1.242 million of convertible note repayments and $8.849 million of operating cash use. Financing brought in $12.657 million during the nine months against $8.849 million of operating cash use, and the cash balance rose from $600,000 to $4.437 million. The company raised more than it consumed; the constraint is how little it raised relative to the work still ahead. Form 10-Q, September 30, 2026
The arithmetic of the runway is simple and the company states its conclusion without hedging: additional funds are required within the next twelve months, and the conditions raise substantial doubt about the ability to continue as a going concern. On the nine-month operating rate of $8.849 million, the September cash balance corresponds to roughly four and a half months, a Merlintrader calculation that measures a historical average rather than a forecast. The rate itself is not stable: the third-quarter operating cash use was lower than the first half’s, because research spending has been cut. A shrinking burn extends the runway and also slows the programs that need to produce the evidence. Form 10-Q, September 30, 2026
Three sources of money are available to the company and each has a cost. The at-the-market program with H.C. Wainwright allows sales of up to $6.53 million of common stock at a 3.0% commission, on top of a $75 million shelf registration statement filed in May 2026; that is the cheapest route administratively and the most expensive in dilution at the current price level. The March 2026 private placement raised $10.997 million in gross proceeds through shares, pre-funded warrants and common warrants, and the common warrants carry an exercise price of $28.80. A partnership or license would bring money without issuing equity, which is why the company’s language about strategic partners matters more than it might appear. Form 10-Q, September 30, 2026
11 Debt, leases, the Craft arbitration and the listing rule
The debt position is now clean, which is a genuine improvement. Convertible notes of $437,000 and related-party convertible notes of $172,000 at December 31, 2025 were repaid during 2026, leaving no convertible debt on the September 30 balance sheet and total liabilities of $439,000: $284,000 of trade payables, $115,000 due to related parties and $40,000 of current lease liabilities. For a company in Artelo’s position, the absence of debt service is meaningful: every dollar of a new raise goes to programs and overhead rather than to creditors. Form 10-Q, September 30, 2026
The lease obligations are small but long. The Solana Beach lease runs through August 2027, and the Manchester office lease runs through September 2031, with a termination option at the end of September 2029; the undiscounted base rent over the non-cancellable term through September 2029 is approximately $45,000. Those commitments do not threaten the balance sheet. The arbitration does. On April 7, 2026 Craft Capital Management filed a claim in FINRA arbitration alleging that Artelo breached a right of first refusal in a March 16, 2026 engagement letter after terminating it on March 27 and closing the March 30 private placement. Craft seeks a success fee of $880,000, warrants valued at $880,000, late fees, attorneys’ fees and interest. Artelo filed counterclaims on July 7, 2026 alleging fraudulent inducement, breach of contract and regulatory violations. The proceedings are ongoing and no liability has been recorded. Form 10-Q, September 30, 2026
The listing question is separate from the operating one. On October 9, 2026 the company reported that the SEC had approved Nasdaq’s $5 million market value of listed securities rule on July 22, 2026, that a temporary stay had been announced on July 29, that Nasdaq had proposed moving the operative date to the end of the stay in a notice published for comment on October 5 with comments due October 29, and that the company had no information on how long the stay would last. The report also said Artelo was among roughly 180 Nasdaq companies initially identified below the threshold, and that it had not committed to any course of action. That is a procedural position, not a compliance comfort: a company whose market value stays below the threshold remains exposed to a deficiency notice and to the reverse split mechanism that has already been used twice, in June 2025 at one-for-six and in August 2026 at one-for-nine. Form 8-K, October 9, 2026
12 Share dilution: a denominator that has moved twice in fifteen months
The share count is the clearest measure of what has happened to holders. Artelo executed a one-for-six reverse split effective June 13, 2025, reducing outstanding shares from 3,280,000 to approximately 546,667, and a one-for-nine reverse split with adjusted trading from August 31, 2026. The second split consolidated 4,929,966 shares into approximately 603,396, and the count at September 30 was 937,177: the increase came from 416,189 shares issued for cash during the quarter, not from the consolidation. Shares outstanding were 937,177 on November 11, 2026, and authorized common stock is 55,555,556. Form 10-Q, September 30, 2026 Form 8-K, August 27, 2026
What sits behind the outstanding count is more important than the count itself. At September 30 there were 784,424 warrants outstanding with a weighted average exercise price of $37.16 and a weighted average remaining life of 4.93 years, all exercisable, with an intrinsic value of zero at that date. The March placement created 345,268 pre-funded warrants at an exercise price of $0.009 and 708,536 common warrants at $28.80; during the nine months 349,550 warrants were exercised, most of them pre-funded. There were also 22,902 options outstanding at a weighted average exercise price of $139.86 under a 2018 plan that permits up to 23,644 shares, of which 742 remained available. Form 10-Q, September 30, 2026
Those instruments matter in two directions. If the shares trade well below the warrant exercise prices, the warrants are unlikely to be exercised and act as a ceiling rather than a source of cash; the company disclosed that the intrinsic value was zero at September 30. If the shares recover toward those prices, exercises add cash and add shares at the same time. The authorized count of 55.5 million against 937,177 outstanding gives the company enormous room to issue, and the shelf and ATM provide the mechanism. A holder’s fractional claim on any eventual success is therefore a function of how many more shares are sold before that success arrives. Form 10-Q, September 30, 2026
13 Ownership, short interest, red flags and the overall assessment
Institutional ownership is thin and concentrated in the investors who took the March placement. Two amendments to Schedule 13G were filed in August 2026, one on August 13 Schedule 13G/A and one on August 14 Schedule 13G/A, and the placement participants in the March offering were accredited investors. Short interest was 27,721 shares at the October 30, 2026 settlement, about 3.0% of the 937,177 shares outstanding, a Merlintrader calculation from the Nasdaq settlement figure. On a base this small, a short position of that size can move the tape in both directions without implying a view about the company. Form 10-Q, September 30, 2026
Four red flags deserve to be stated without decoration. First, the going-concern paragraph has appeared in consecutive filings and is written in the plainest terms available to an auditor and a finance team. Second, research spending has been cut by nearly half while administrative expense has grown, which is the pattern of a company preserving its corporate shell while slowing its science. Third, two reverse splits in fifteen months, followed by a quarter in which the share count rose, is a dilution history rather than a dilution risk. Fourth, the Craft arbitration seeks amounts equal to roughly forty per cent of the September cash balance, and an adverse outcome would be settled in a period when cash is the binding constraint. Form 10-Q, September 30, 2026
The overall assessment is that Artelo is a legitimate research organization with a plausible mechanism, an unusual amount of optionality for its size, and a balance sheet that cannot fund the work needed to convert that optionality into value. The mechanism is supported by independent literature on fatty acid binding proteins and on cannabinoid effects on intraocular pressure; the company has human safety data for both lead molecules; and it has patent claims moving toward issuance. Against that, it has four and a half months of historical cash, a research budget that has been halved, a going-concern qualification, and a share structure that has been reorganized twice. The next two disclosures — DREAM and the ART26.12 dose escalation — will decide whether the options are exercised by the company or sold to a partner. Form 10-Q, September 30, 2026
Merlintrader Health Score · $ARTL
1.60out of 5
Assessed October 2, 2026; reassessed November 12, 2026 after the third-quarter report and again on November 22, 2026: cash of $4.437 million, continuing going-concern doubt and ATM issuance leave every pillar score unchanged. Weighted calculation: 1.0×30% + 2.5×30% + 1.0×20% + 1.5×10% + 2.0×10% = 1.60. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Historical cash is not a current cash balance; subsequent spending and financing matter.
- Company milestones remain conditional where explicitly identified as plans or targets.
- The funding gap is the binding constraint: $4.437 million of cash at September 30, 2026 against $8.849 million of nine-month operating use, with going-concern doubt stated in the quarterly report.
ARTL Stock FAQ: Artelo Biosciences Questions Answered
When is the next ARTL stock catalyst?
As of November 12, 2026, Artelo’s next stated catalyst is initial results from the DREAM glaucoma study, targeted on August 10 for Q4 2026 without an exact date; the November 12 update reported enrollment underway and did not restate a results date. The ART26.12 multiple ascending dose study is planned to initiate in Q4 2026. These development targets depend on execution and funding. Artelo presented ART26.12 data at BIO-Europe 2026, a partnering event rather than a clinical readout, on November 10. DREAM timing. ART26.12 clinical plans. BIO-Europe presentation.
Are Artelo Biosciences’ drug candidates FDA approved?
No: as of November 12, 2026, Artelo’s candidates remain investigational. ART26.12 is advancing in early clinical development for pain, while ART27.13 is being studied in cancer supportive care and glaucoma. Clinical observations and nonclinical obesity findings are development evidence, rather than marketing approvals. Clinical pipeline. Nonclinical obesity program.
How much cash does Artelo Biosciences have, and how long will it last?
Artelo held $4.437 million cash at September 30, 2026, against nine-month operating cash use of $8.849 million, averaging about $0.983 million monthly (Merlintrader calculation). That gives a historical ratio of approximately four and a half months from September, before later financing and spending. The November 12 quarterly report discloses substantial going-concern doubt. DREAM’s external study funding does not cover all corporate expenses or other programs. Liquidity, cash flow and going concern. Externally funded DREAM study.
Did Artelo’s reverse stock split dilute shareholders?
Artelo’s one-for-nine reverse split began adjusted trading on August 31, 2026, consolidating existing shares rather than itself raising capital. The split reduced outstanding shares to approximately 603,396; the quarterly report shows 937,177 shares outstanding on November 11, 2026. Authorized common shares were reduced to 55,555,556. Convertible securities, warrants, equity awards and future financings can still increase the common-share count; the reverse split does not remove those sources of dilution. Reverse-split and charter terms. Adjusted trading date. Financing instruments and risks.
When does Artelo Biosciences report earnings?
Artelo Biosciences reported third-quarter 2026 results on November 12, 2026 and filed its quarterly report for the period ended September 30 the same day; it had not announced its next financial-results date. The November 10 BIO-Europe presentation was a company and partnering event, rather than a financial-results release. Latest quarterly filing. Third-quarter release. Separate BIO-Europe presentation. Company announcements.
What does Artelo Biosciences do?
Artelo Biosciences develops medicines targeting lipid-signaling pathways. Its pipeline includes the FABP5 inhibitor ART26.12 for pain, cannabinoid receptor agonist ART27.13 for cancer supportive care and other indications, and the ART12.11 CBD cocrystal program. The company remains in clinical and preclinical development.
Were Artelo’s obesity results from human patients?
No: Artelo’s September 16 and 23, 2026 announcements concern obese mice, not patients. The reported observations were approximately 20% weight loss with ART27.13 alone and 40% with semaglutide combination treatment over four weeks. These nonclinical results are not proof of human weight-loss efficacy. Mouse-study results and September announcements.
Did Artelo’s CAReS trial provide confirmatory evidence?
No: Artelo’s annual report describes September 3, 2025 interim CAReS findings from 18 evaluable patients, with a highest-dose comparison involving five treated and six placebo participants. The small interim analysis is not a large confirmatory efficacy result. Its population and analysis limits matter when interpreting the reported body-weight signal. CAReS interim population and dose comparison.
Primary sources
- November 12, 2026 — Business update and third-quarter 2026 results
- November 12, 2026 — Form 10-Q for the quarter ended September 30, 2026: cash, ATM sales and going-concern disclosure
- October 29, 2026 — ART27.13 nonclinical pain work presented at IASP
- October 26, 2026 — ART26.12 data scheduled at the IASP 2026 World Congress on Pain on October 29
- October 9, 2026 — Nasdaq proposed $5 million MVLS rule is stayed; no immediate delisting decision
- October 7, 2026 — First company presentation at BIO-Europe, November 10
- September 23, 2026 — provisional obesity patent application
- September 16, 2026 — unexpected mouse weight-loss results
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent educational research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ARTL or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



